EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
SECTION 06 OF 12 / Monitor

Expert Q&A

Prepare the questions that need specialist judgement.

22Pages
37Sources cited
17 Nov 2026Last updated
A small audio recorder and clinical research folder on a consultation table
THE SPECIALIST INTERVIEW AGENDA

Ask the question that changes the decision.

Proposed experts have not been interviewed. These are research-backed questions and answer frameworks.

Proposed experts and areas of expertise →
01

What exactly is the clinic buying—and which expenditure can it control?

Read the question & evidence →
02

Can clinics still prescribe compounded semaglutide or tirzepatide after the shortage—and what would justify this particular preparation?

Read the question & evidence →
03

Can a clinic buy compounded GLP-1 medicine for office use from a 503B outsourcing facility?

Read the question & evidence →
04

What evidence converts ‘nationwide coverage’ into a reliable state-expansion plan?

Read the question & evidence →
05

What does a credible GLP-1 supplier quality review contain beyond licences and a certificate of analysis?

Read the question & evidence →
06

Who owns cold-chain failures, concentration changes and dosing-instruction errors?

Read the question & evidence →
07

Which DSCSA and provenance responsibilities apply to this arrangement?

Read the question & evidence →
08

When is manufacturer-linked access preferable to an integrated pharmacy partner?

Read the question & evidence →
09

How should a clinic compare GLP-1 pharmacy quotes without being misled by introductory prices?

Read the question & evidence →
10

What should ‘cost per successfully fulfilled patient-month’ actually mean?

Read the question & evidence →
11

Which service levels reveal whether a pharmacy can support our growth?

Read the question & evidence →
12

Is our backup pharmacy genuinely independent—and can it absorb a disruption?

Read the question & evidence →
13

How do we change pharmacy partners without turning an operational migration into an unsafe treatment switch?

Read the question & evidence →
14

Which contract clauses protect continuity when regulation, price or performance changes?

Read the question & evidence →
15

What data and integration rights does the clinic need without misclassifying HIPAA relationships?

Read the question & evidence →
16

Could referral fees, prescribing incentives or exclusivity undermine the arrangement?

Read the question & evidence →

The full interview brief

20 pages shown

Research quality self-assessment
9 / 10buyer fit
9 / 10depth
9 / 10search terms
8 / 10sources

The research’s own assessment; not an external rating.